FABP4 and endothelial dysfunction: In addition, we recently demonstrated that high levels of plasma FABP4, as well as other inflammation mediators, were associated with endothelial dysfunction as assessed by peripheral artery tonometry[27,28], and in an in vitro study, we previously demonstrated that recombinant FABP4 causes endothelial dysfunction by impairing the insulin-signalling pathway and NO production[29].